Daehan New Pharm Co (XKRX:054670) 5-Year EBITDA Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Daehan New Pharm Co 5-Year EBITDA Growth Rate?

Daehan New Pharm Co's EBITDA per Share for the three months ended in Sep. 2024 was ₩270.06.

During the past 12 months, Daehan New Pharm Co's average EBITDA Per Share Growth Rate was -27.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Daehan New Pharm Co was 135.80% per year. The lowest was -35.40% per year. And the median was 9.35% per year.

Competitive Comparison of Daehan New Pharm Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Daehan New Pharm Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daehan New Pharm Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daehan New Pharm Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Daehan New Pharm Co's 5-Year EBITDA Growth Rate falls into.

Daehan New Pharm Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Daehan New Pharm Co (XKRX:054670) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Daehan New Pharm Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Daehan New Pharm Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Daehan New Pharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daehan New Pharm Co Ltd (XKRX:054670) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

1062-4 Namhyeon-dong, Gwanak-gu, Seoul, KOR, 137-851

Website

http://www.dhnp.co.kr

Daehan New Pharm Co Ltd is a South Korea based company operating in the pharmaceutical sector. It is engaged in producing pharmaceutical products, animal health and nutrition, and bio products. The pharmaceutical products are tertan tab, amloc tab, tarocin SR tab, NP star tab and others. The animal health and nutrition products are starvac, pigcoc for calves, ocean doctor, and others. The bio range of the products by the group are CELRENA serum-free, BMPro serum-free, BMPro-V serum-free, ALyS505NK-EX serum-free and others.

Daehan New Pharm Co Headlines

No Headlines